Advertisement

International Journal of Hematology

, Volume 101, Issue 2, pp 114–118 | Cite as

Increase of serum fractalkine and fractalkine gene expression levels in sickle cell disease patients

  • Selma Unal
  • Ozlem Ozdemir
  • Ahmet Ata Ozcimen
  • Yesim OztasEmail author
Original Article

Abstract

In the present study, we examined the role of fractalkine (Fkn), a member of the chemokine family, in the pathogenesis of sickle cell disease (SCD). Eighty-seven children with sickle cell disease and 55 healthy children were enrolled in the study. Complete blood counts, serum levels of C-reactive protein, tumor necrosis factor-α, interferon-γ and fractalkine, and gene expression levels of Fkn were investigated. Serum Fkn levels and Fkn gene expression values were significantly higher in the SCD group compared to control group (P < 0.05). The findings of elevated serum Fkn and Fkn gene expression in both vaso-occlusive crisis and stable forms of SCD suggest that this chemokine may be involved in the pathogenesis of inflammation observed in SCD. This study is the first to our knowledge to describe the relationship of Fkn and inflammation in SCD.

Keywords

Sickle cell disease Inflammation Fractalkine Cytokine Chemokine 

References

  1. 1.
    Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005;293:1653–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Makis AC, Hatzimichael EC, Bourantas KL. The role of cytokines in sickle cell disease. Ann Hematol. 2000;79:407–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin. 1995;19:323–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337–8.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Pathare A, Al Kindi S, Alnaqdy AA, Daar S, Knox-Macaulay H, Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol. 2004;77:323–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Pathare A, Kindi SA, Daar S, Dennison D. Cytokines in sickle cell disease. Hematology. 2003;8:329–37.PubMedCrossRefGoogle Scholar
  7. 7.
    Bourantas KL, Dalekos GN, Makis A, Chaidos A, Tsiara S, Mavridis A. Acute phase proteins and interleukins in steady state sickle cell disease. Eur J Haematol. 1998;61:49–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Belcher JD, Bryant CJ, Nguyen J, Bowlin PR, Kielbik MC, Bischof JC, Hebbel RP, Vercellotti GM. Transgenic sickle mice have vascular inflammation. Blood. 2003;101:3953–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Vercellotti GM, Belcher JD. Not simply misshapen red cells: multimolecular and cellular events in sickle vaso-occlusion. J Clin Invest. 2014;124:1462–5.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Wojdasiewicz P, Poniatowski LA, Kotela A, Deszczynski J, Kotela I, Szukiewicz D. The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Arch Immunol Ther Exp (Warsz). 2014;62:395–403.CrossRefGoogle Scholar
  11. 11.
    White GE, Greaves DR. Fractalkine: one chemokine, many functions. Blood. 2009;113:767–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, Lira SA, Weissman IL, Weber C, Jung S. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood. 2009;113:963–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Avni T, Paret G, Thaler A, Mishali D, Yishay S, Tal G, Dalal I. Delta chemokine (fractalkine)–a novel mediator of pulmonary arterial hypertension in children undergoing cardiac surgery. Cytokine. 2010;52:143–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Jones BA, Riegsecker S, Rahman A, Beamer M, Aboualaiwi W, Khuder S, Ahmed S. Role of ADAM-17, p38 MAPK, cathepsins, and the proteasome pathway in the synthesis and shedding of fractalkine/CX3CL1 in rheumatoid arthritis. Arthritis Rheum. 2013;65:2814–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Fujimoto K, Imaizumi T, Yoshida H, Takanashi S, Okumura K, Satoh K. Interferon-gamma stimulates fractalkine expression in human bronchial epithelial cells and regulates mononuclear cell adherence. Am J Respir Cell Mol Biol. 2001;25:233–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24:34–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, Okazaki T, Domae N, Fujimoto H, Minami Y, Kono T, Bloom ET, Umehara H. Membrane-bound form of fractalkine induces IFN-γ production by NK cells. Eur J Immunol. 2003;33:53–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Jang JE, Hod EA, Spitalnik SL, Frenette PS. CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions. J Clin Invest. 2011;121:1397–401.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Qari MH, Dier U, Mousa SA. Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost. 2012;18:195–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Driss A, Wilson NO, Mason K, Hyacinth HI, Hibbert JM, Serjeant GR, Stiles JK. Elevated IL-1alpha and CXCL10 serum levels occur in patients with homozygous sickle cell disease and a history of acute splenic sequestration. Dis Markers. 2012;32:295–300.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Ostadebrahimi H, Jamali Z, Nazari M, Bahri M, Farahmandnia Z, Khandany BK, Taheri M, Khorramdelazad H, Hakimizadeh E, Zaker F, Rezaeian M, Hassanshahi G. CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 are variably expressed in patients with sickle cell disease and carriers: are they predictive tools for disease complications? Clin Lab. 2014;60:99–104.PubMedGoogle Scholar
  22. 22.
    Veiga PC, Schroth RJ, Guedes R, Freire SM, Nogueira-Filho G. Serum cytokine profile among Brazilian children of African descent with periodontal inflammation and sickle cell anaemia. Arch Oral Biol. 2013;58:505–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–63.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Raghupathy R, Haider MZ, Azizieh F, D’Souza TM, Abdelsalam R, Adekile AD. Tumor necrosis factor-alpha is undetectable in the plasma of SS patients with elevated Hb F. Am J Hematol. 2000;64:91–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Yajima N, Kasama T, Isozaki T, Odai T, Matsunawa M, Negishi M, Ide H, Kameoka Y, Hirohata S, Adachi M. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum. 2005;52:1670–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Perros F, Dorfmuller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Herve P, Simonneau G, Emilie D, Humbert M. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J. 2007;29:937–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Blaschke S, Koziolek M, Schwarz A, Benohr P, Middel P, Schwarz G, Hummel KM, Muller GA. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003;30:1918–27.PubMedGoogle Scholar
  28. 28.
    Dimberg J, Dienus O, Lofgren S, Hugander A, Wagsater D. Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. Int J Colorectal Dis. 2007;22:1195–200.PubMedCrossRefGoogle Scholar
  29. 29.
    Rimaniol AC, Till SJ, Garcia G, Capel F, Godot V, Balabanian K, Durand-Gasselin I, Varga EM, Simonneau G, Emilie D, Durham SR, Humbert M. The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol. 2003;112:1139–46.PubMedCrossRefGoogle Scholar
  30. 30.
    Alexander RW. Cytokine receptor CX3CR-1 and fractalkine: new factors in the atherosclerosis drama? Circ Res. 2001;89:376–7.PubMedGoogle Scholar
  31. 31.
    Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol. 2000;18:593–620.PubMedCrossRefGoogle Scholar
  32. 32.
    Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum. 2006;54:3408–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Niessner A, Marculescu R, Kvakan H, Haschemi A, Endler G, Weyand CM, Maurer G, Mannhalter C, Wojta J, Wagner O, Huber K. Fractalkine receptor polymorphisms V2491 and T280 M as genetic risk factors for restenosis. Thromb Haemost. 2005;94:1251–6.PubMedGoogle Scholar
  34. 34.
    Flierl U, Schafer A. Fractalkine–a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost. 2012;108:457–63.PubMedCrossRefGoogle Scholar
  35. 35.
    Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, Melville L, Melrose LA, Ogden CA, Nibbs R, Graham G, Combadiere C, Gregory CD. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008;112:5026–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Corcione A, Ferretti E, Pistoia V. CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol. 2012;92:51–8.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2014

Authors and Affiliations

  • Selma Unal
    • 1
  • Ozlem Ozdemir
    • 1
  • Ahmet Ata Ozcimen
    • 2
  • Yesim Oztas
    • 3
    Email author
  1. 1.Department of Pediatric Hematology, Faculty of MedicineMersin UniversityMersinTurkey
  2. 2.Department of Biology, Faculty of Science and LiteratureMersin UniversityMersinTurkey
  3. 3.Department of Biochemistry, Faculty of MedicineHacettepe UniversityAnkaraTurkey

Personalised recommendations